Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 7/20 | 0.46 |
| ▸ | FAP | Q12884 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201078 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL28833359 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL163395 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL122347 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL159315 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL250459 | 1.00 | ALDH1A1 (0.50) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL17338009 | 0.98 | ALDH1A1 (0.48) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL15268412 | 0.98 | ALDH1A1 (0.48) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL17338024 | 0.98 | ALDH1A1 (0.48) | ALDH1A1DPP7KDM4EEPHX1NPC1 | |
| SCHEMBL22029349 | 0.98 | ALDH1A1 (0.48) | ALDH1A1DPP7KDM4EEPHX1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1998 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1621546-B1 | Peptide ligands specific to immonoglobulins | TECNOGEN SPA (IT) | 2008-10-29 | — | — | EP | claimed |
| US-7256172-B1 | Method of treatment and agents useful for same | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-14 | — | — | US | claimed |
| EP-1621546-A1 | Peptide ligands specific to immonoglobulins | TECNOGEN S.C.P.A. (IT) | 2006-02-01 | — | — | EP | claimed |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-05-21 | — | — | US | disclosed |
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | ENTERA BIO LTD. (IL) | 2026-05-07 | — | — | US | disclosed |
| WO-2026085582-A1 | PROTEIN CAGES | THE UNIVERSITY OF SYDNEY (AU) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2026-04-23 | — | — | US | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| US-12605425-B2 | TNF muteins and uses thereof | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2026-04-21 | — | — | US | disclosed |
| EP-4710935-A2 | NOVEL IMMUNOTHERAPEUTIC COMPOSITION AND USES THEREOF | Aravax Pty Ltd (AU) | 2026-03-18 | — | — | EP | disclosed |
| EP-0745092-A1 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1996-12-04 | — | — | EP | disclosed |
| WO-1996024609-A1 | THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1996-08-15 | — | — | WO | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| WO-1995027729-A1 | OPIATE RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-10-19 | — | — | WO | disclosed |
| EP-0672049-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994028014-A2 | PEPTIDE INHIBITORS OF UROKINASE RECEPTOR ACTIVITY | CHIRON CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994011388-A1 | SUPPORT FOR THE SYNTHESIS OF MODULAR POLYMERS | CHIRON MIMOTOPES PTY. LTD. (AU) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994003483-A1 | ENDOTHELIN RECEPTOR-BINDING COMPOUNDS | CHIRON CORPORATION (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124281-A1 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | PTH1R, FGF23, PTMS | ALDH1A1 2763/4885DPP7 2428/4885KDM4E 2999/4885 |
| US-12605425-B2 | TNF muteins and uses thereof | TNFRSF1A, TNF, TNFSF11 | ALDH1A1 4618/4885DPP7 4016/4885KDM4E 3492/4885 |
| US-20260109870-A1 | PEPTIDE-BASED NON-CRYSTALLINE MATERIALS AND COMPOSITIONS AND PROCESSES FOR OBTAINING SAME | NONO, NGLY1, PTMS | ALDH1A1 4370/4885DPP7 537/4885KDM4E 1513/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | ALDH1A1 3922/4885DPP7 197/4885KDM4E 1225/4885 |
| US-20260140060-A1 | COLORIMETRIC DETECTION OF A VIRAL INFECTION | CTSL, CPA4, ACE2 | ALDH1A1 1754/4885DPP7 86/4885KDM4E 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.